8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF

THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of Earliest Event Reported): December 4, 2015

Quest Diagnostics Incorporated

(Exact Name of Registrant as Specified in Its Charter)

Delaware

(State or other jurisdiction of Incorporation)

001-12215	16-1387862
(Commission File Number)	(I.R.S. Employer Identification No.)
Three Giralda Farms Madison, NJ 07940	07940
(Address of principal executive offices)	(Zip Code)
(973) 520-2700
(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

[ ]	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ]	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ]	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ]	Pre-commencement communications pursuant to Rule 13e-4(c) under the exchange Act (17 CFR 240.13e-4(c))

Item 8.01 Other Events

On December 4, 2015, Quest Diagnostics Incorporated (the “Company”) issued a press release announcing that the Company's Board of Directors authorized the Company to repurchase an additional $500 million of the Company's common stock as part of the Company's common stock repurchase program. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits

(d)	Exhibit	Description
	99.1	Press release of Quest Diagnostics Incorporated dated December 4, 2015, announcing that the Company's Board of Directors authorized the Company to repurchase an additional $500 million of the Company's common stock.

Signature

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

December 4, 2015

QUEST DIAGNOSTICS INCORPORATED

By:/s/ William J. O'Shaughnessy, Jr.

William J. O'Shaughnessy, Jr.

Deputy General Counsel and Secretary

2

EX-99.1

Exhibit 99.1

Quest Diagnostics Increases Share Repurchase Authority by $500 Million

MADISON, N.J., Dec. 4, 2015 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that its Board of Directors has increased the company's share repurchase authorization by $500 million.

The $500 million authorization announced today is an increase to the $522 million that was available as of Sept. 30, 2015 under the company's share repurchase authorization program. Fourth quarter repurchases will be reported when quarterly earnings are announced Jan. 28, 2016.

"The increase in our share repurchase authorization is consistent with our long-term disciplined capital deployment strategy, which includes returning the majority of our free cash flow to shareholders through dividends and stock repurchases," said Steve Rusckowski, President and CEO.

About Quest Diagnostics
Quest Diagnostics empowers people to take action to improve health outcomes.  Derived from the world's largest database of clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve health care management.  Quest annually serves one in three adult Americans and half the physicians and hospitals in the United States, and our 45,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives. www.QuestDiagnostics.com.

Quest Diagnostics Contacts:
Dan Haemmerle (Investors): 973-520-2900
Denny Moynihan (Media): 973-520-2800